Telemedicine Clinic for Prostate Cancer Patients

NCT03413865 | Unknown DMC

• 1 other identifier: OTN Study
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

This randomized, open label study will evaluate a nurse and pharmacist led clinic conducted remotely from Grand River Regional Cancer Centre at Grand River Hospital (GRRCC/GRH) using OTN teleconferencing as a platform for patients with prostate cancer receiving oral chemotherapy agents.

Conditions

Cancer, Treatment-Related

Outcome Measures

Primary Outcomes (1)

• Patient satisfaction with overall care

  The primary outcome will be a comparison of patient satisfaction with overall care utilizing a validated scale between the group of patients using the OTN clinic and a group of control patients receiving conventional care at GRRCC

  2 Years

Study Arms (2)

OTN virtual clinic

EXPERIMENTAL

Pharmacist and nurse led OTN based remote teleconference based clinic (OTN) The OTN clinic will be conducted by providing the patient with a link via email which will allow the patient to access OTN teleconferencing and meet virtually with a pharmacist and nurse during a previously scheduled appointment. Virtual clinic appointments will be 30 minutes long and will consist of a patient assessment and open ended questions about the patient health status using a modified version of the validated MOATT (MASCC Oral Agent Teaching Tool) created by the Multidisciplinary Association of Supportive Care in Cancer.

Other: Visits conducted via Telemedicine

In person Visits

NO INTERVENTION

Patients are followed in person at the cancer clinic based on standard of care guidelines

Interventions

Visits conducted via Telemedicine OTHER

Patients will be followed via telemedicine with visits lead by a Pharmacist and a Nurse

OTN virtual clinic

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: Prostate Cancer Patients
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male over 18 years of age with prostate cancer receiving oral treatment with abiraterone or enzalutamide.
• Ability to provide consent to study.
• Willingness to complete study questionnaires and a semi-structured exit interview.
• Adequate command of the English language to complete study questionnaire and survey.
• Access to technology to allow a link to the virtual telemedicine clinic. (excluding control group)
• Willingness to participate in videoconference with pharmacist or nurse from their home environment. (excluding control group)

You may not qualify if:

• Patients receiving oral anti-cancer therapy other than abiraterone and enzalutamide.
• Patients lacking the technology at home to participate in the virtual telemedicine clinic. (excluding control group)

Sponsors & Collaborators

• Grand River Hospital: lead

Study Sites (1)

Grand River Hospital

Kitchener, Ontario, Canada

RECRUITING

MeSH Terms

Conditions

Neoplasms, Second Primary

Condition Hierarchy (Ancestors)

Neoplasms

Central Study Contacts

Stacey Hubay, MD, FRCPC

CONTACT

519-749-4370; stacey.hubay@grhosp.on.ca

Carla Girolametto, MA, MHSC

CONTACT

519-749-4370; carla.girolametto@grhosp.on.ca

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 12, 2018
• First Posted: January 29, 2018
• Study Start: October 28, 2016
• Primary Completion: October 1, 2020
• Study Completion: June 1, 2021
• Last Updated: February 15, 2019

Record last verified: 2019-02

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)